Zacks Research Estimates Medifast FY2028 Earnings

Medifast Inc (NYSE:MED) – Analysts at Zacks Research issued their FY2028 earnings per share (EPS) estimates for shares of Medifast in a research note issued to investors on Tuesday, March 10th. Zacks Research analyst Team expects that the specialty retailer will post earnings per share of ($1.83) for the year. The consensus estimate for Medifast’s current full-year earnings is $0.51 per share.

Medifast (NYSE:MED) last issued its quarterly earnings results on Tuesday, February 17th. The specialty retailer reported ($0.55) earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of ($0.76) by $0.21. The company had revenue of $75.10 million for the quarter, compared to analyst estimates of $71.40 million. Medifast had a negative net margin of 4.84% and a negative return on equity of 4.27%. Medifast has set its FY 2026 guidance at -2.750–1.55 EPS and its Q1 2026 guidance at -0.700–0.15 EPS.

Several other equities analysts also recently commented on the stock. Wall Street Zen downgraded shares of Medifast from a “hold” rating to a “sell” rating in a research note on Saturday, February 21st. Stephens decreased their target price on Medifast from $15.00 to $12.00 and set an “equal weight” rating for the company in a report on Thursday, February 19th. Finally, Weiss Ratings reissued a “sell (d)” rating on shares of Medifast in a research note on Thursday, January 22nd. One analyst has rated the stock with a Hold rating and one has assigned a Sell rating to the stock. Based on data from MarketBeat, the company currently has an average rating of “Reduce” and an average price target of $12.00.

Medifast Stock Performance

Shares of MED stock opened at $10.71 on Wednesday. The stock has a market capitalization of $117.69 million, a P/E ratio of -6.26 and a beta of 0.52. The company has a 50 day moving average price of $11.07 and a 200 day moving average price of $12.03. Medifast has a fifty-two week low of $10.10 and a fifty-two week high of $15.46.

Institutional Inflows and Outflows

Several institutional investors and hedge funds have recently made changes to their positions in the business. Charles Schwab Investment Management Inc. raised its position in shares of Medifast by 30.5% during the 4th quarter. Charles Schwab Investment Management Inc. now owns 776,829 shares of the specialty retailer’s stock worth $8,297,000 after acquiring an additional 181,618 shares in the last quarter. Bank of America Corp DE boosted its holdings in Medifast by 14.2% in the third quarter. Bank of America Corp DE now owns 452,543 shares of the specialty retailer’s stock valued at $6,186,000 after purchasing an additional 56,174 shares in the last quarter. Acadian Asset Management LLC boosted its holdings in Medifast by 6.6% in the second quarter. Acadian Asset Management LLC now owns 411,101 shares of the specialty retailer’s stock valued at $5,769,000 after purchasing an additional 25,378 shares in the last quarter. Lido Advisors LLC acquired a new position in Medifast in the third quarter valued at approximately $4,521,000. Finally, Dimensional Fund Advisors LP increased its stake in Medifast by 9.3% in the fourth quarter. Dimensional Fund Advisors LP now owns 326,240 shares of the specialty retailer’s stock valued at $3,484,000 after purchasing an additional 27,871 shares during the last quarter. 95.51% of the stock is owned by institutional investors and hedge funds.

Medifast Company Profile

Medifast, Inc (NYSE: MED) is a health and wellness company specializing in clinically supported weight-loss, weight-management and healthy living products and services. Through its OPTAVIA brand, the company offers a range of meal replacement products, snacks, supplements and coaching programs designed to support metabolic health and sustainable lifestyle changes. Medifast markets its products directly to consumers via a network of independent distributors—known as OPTAVIA Coaches—who provide personalized guidance and support throughout the client’s weight‐loss journey.

Founded in 1980 by William Vitale and headquartered in Baltimore, Maryland, Medifast has grown into a nationally recognized provider of nutrition and weight‐management solutions.